^
    Back
    Association details:
    Biomarker:BCL2L11 deletion + EGFR T790M
    Cancer:Non Small Cell Lung Cancer
    Drug:Tagrisso (osimertinib) (EGFR inhibitor)
    Direction:Resistant
    Evidence:
    Evidence Level:
    Resistant: C3 – Early Trials
    New
    Source:
    Lung Cancer
    Title:

    Clinical implications of germline BCL2L11 deletion polymorphism in pretreated advanced NSCLC patients with osimertinib therapy

    Published date:
    12/03/2020
    Excerpt:
    BIM-del was detected in only 17.5 % of T790M-positive patients (25/143)….BIM-del was associated with a significantly shorter progression-free survival (PFS) and a moderately shorter overall survival (OS) (8.3 versus 10.5 months, p = 0.031 and 15.9 versus 25.2 months, p = 0.1, respectively).
    DOI:
    10.1016/j.lungcan.2020.12.002
    Evidence Level:
    Resistant: C3 – Early Trials
    Source:
    ASTRO 2020
    Title:

    2195 Association between BIM Deletion Polymorphism and Efficacy of Osimertinib in Advanced EGFR T790M NSCLC Patients

    Published date:
    11/01/2020
    Excerpt:
    Patients with BIM-del had a poor objective response rate compared to those without (29% vs. 57%, P = 0.012). BIM-del was associated with shorter progress free survival (PFS) and overall survival (OS). (PFS, 8.3 vs. 10.4 months, P = 0.042; OS, 14.8 vs. 23.4 months, P = 0.005)....BIM-del was associated with inferior efficacy and may serve as a negative predictive biomarker to osimertinib in EGFR T790M NSCLC patients.